Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of venetoclax plus fludarabine/cytarabine/gemtuzumab ozogamicin in children with relapsed AML
NL-OMON51670Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Feb 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, fludarabine, cytarabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Overall survival. Started Feb 2023; status: recruiting.
02
Drugs
venetoclaxfludarabinecytarabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON51670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51670.